Innovations protected by issued and pending patents.
2024 · pending · WO2025222056A1
Compositions comprising oligonucleotides (siRNA or ASO) that target CDHR3 for treating conditions associated with CDHR3 variants.
2024 · pending · WO2025240505A1
Compositions comprising oligonucleotides (siRNA or ASO) that target COLGALT2 for treating conditions associated with COLGALT2 variants.
2024 · pending · WO2025240482A1
Compositions comprising oligonucleotides (siRNA or ASO) that target CSPG4 for treating conditions associated with CSPG4.
2024 · pending · WO2025240499A1
Compositions comprising oligonucleotides (siRNA or ASO) that target PLOD2 for treating conditions associated with PLOD2.
2023 · pending · WO2024206673A3
Compositions comprising oligonucleotides (siRNA or ASO) that target FGG for the treatment of hearing disorders.
2023 · pending · WO2025137323A1
Compositions comprising oligonucleotides (siRNA or ASO) that target CPN1 for treating conditions associated with CPN1 gene mutations.
2022 · pending · WO2023178264A2
Compositions comprising oligonucleotides (siRNA or ASO) that target HGFAC for the treatment of cancer and related diseases.
2022 · pending · EP4544052A1
Compositions comprising oligonucleotides (siRNA or ASO) that target GPAM for the treatment of metabolic disorders including liver disorders and cardiovascular conditions.
2022 · pending · EP4540391A2
MS4A4E inhibitors including oligonucleotides (siRNA or ASO) for the treatment of conditions associated with MS4A4E mutations.
2022 · pending · WO2024091874A1
Gene therapy compositions and methods for treating conditions associated with MTRES1 gene mutations.
2022 · pending · MX2025006351A
Compositions comprising oligonucleotides (siRNA or ASO) that target MTRES1 for treating conditions associated with MTRES1 gene mutations.
2022 · pending · US20250333732A1
Compositions comprising oligonucleotides (siRNA or ASO) that target SOS Ras/Rho guanine nucleotide exchange factor 2 (SOS2) for the treatment of related conditions.
2022 · pending · WO2024091873A3
Small molecule compositions that target MTRES1 for treating conditions associated with MTRES1 gene mutations.